Virios therapeutics announces first quarter 2024 financial results and provides corporate update

- top-line results from the ongoing investigator-initiated bateman horne center long-covid phase 2 featuring valacyclovir and celecoxib (imc-2) expected in the second-half of 2024 -
VIRI Ratings Summary
VIRI Quant Ranking